Abiomed, Inc. (NASDAQ: ABMD) today announced availability of its customer Webcast on Best Practices for Anticoagulation with Ventricular Assist Device (VAD) Patients. As part of Abiomed’s expanded customer services offering, the Partnership in Healthcare Program, this educational session on anticoagulation will now be available online at www.abiomed.com and in the Partnership in Healthcare section of the website.
Recovery of native heart function following an acute episode of cardiac failure has been proven to increase with the use of documented post-operative management protocols, including those related to anticoagulation management. In an effort to share best practices around the world and increase recovery awareness, Abiomed presents this workshop, entitled “Anticoagulation 101,” featuring the anticoagulation management experience with Abiomed circulatory support systems. The webcast shares the basics of anticoagulation, such as methods and timing, as well as key clinical strategies to achieve optimal survival and recovery rates. It also includes information on cannulation techniques, graft anastomosis, and establishing hemostasis in both the operating room and intensive care unit.
Webcast presenters include:
- Phil Garwood, CCP, Perfusionist, Lankenau Hospital, Philadelphia
- Daniel H. Raess, MD, Medical Director, Abiomed, Inc.; Former Director of Cardiac Surgery, St. Francis Heart Center, IN; Former Attending Surgeon, Indiana Heart Hospital, IN
- Nadine Brooks, RN, Senior Manager, Clinical Development and Training, Abiomed, Inc.
“Recovery awareness is a strategic priority for Abiomed, and we plan to continue providing educational Webcasts on best-practices and evidence-based medicine to drive improved outcomes and recovery of the native heart for acute patients,” said Michael R. Minogue, Chairman, CEO and President of Abiomed.
In addition, new presentations from Abiomed’s recent STS Symposium, “Making Recovery a Reality,” are now posted on www.abiomed.com. The online symposium contains presentations on the increasing focus on recovery of the native heart, U.S. and European experience with the Impella product portfolio, and perspectives on the AbioCor Total Replacement Heart. Featured speakers include Robert L. Kormos, MD, FAHA, FRCS, from the University of Pittsburgh School of Medicine; Simon R. Dixon, MD, MBchB, FRACP, FACC, from William Beaumont Hospital in Royal Oak, MI; Erik Wassberg, MD, PhD, from the Uppsala University Hospital in Sweden; Mark Anderson, MD, from Robert Wood Johnson University Hospital; and John V. Conte, Jr., MD, from Johns Hopkins in Baltimore.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor® Implantable Replacement Heart. In Europe, Abiomed offers the Impella® LP2.5, Impella® LP5.0, Impella® LD, the Impella® RD and an Intra-Aortic Balloon and the iPulse™ console under CE Mark approval. The Impella® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices and the iPulse™ combination console system are not yet available for sale in the United States. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Company’s most recently filed quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
